The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
Open accessAbstract
Importance There is limited evidence regarding whether the presence of serum antibodies to SARS-CoV-2 is associated with a decreased risk of future infection. Understanding susceptibility to infection and the role of immune memory is important for identifying at-risk populations and could have implications for vaccine deployment. Objective The purpose of this study was to evaluate subsequent evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test (NAAT) among individuals who are antibody-positive compared with those who are antibody-negative, using real-world data. Design This was an observational descriptive cohort study. Participants The study utilized a national sample to create cohorts from a de-identified dataset composed of commercial laboratory test results, open and closed medical and pharmacy claims, electronic health records, hospital billing (chargemaster) data, and payer enrollment files from the United States. Patients were indexed as antibody-positive or antibody-negative according to their first SARS-CoV-2 antibody test recorded in the database. Patients with more than 1 antibody test on the index date where results were discordant were excluded. Main Outcomes/Measures Primary endpoints were index antibody test results and post-index diagnostic NAAT results, with infection defined as a positive diagnostic test post-index, as measured in 30-day intervals (0-30, 31-60, 61-90, >90 days). Additional measures included demographic, geographic, and clinical characteristics at the time of the index antibody test, such as recorded signs and symptoms or prior evidence of COVID-19 (diagnoses or NAAT+) and recorded comorbidities. Results We included 3,257,478 unique patients with an index antibody test. Of these, 2,876,773 (88.3%) had a negative index antibody result, 378,606 (11.6%) had a positive index antibody result, and 2,099 (0.1%) had an inconclusive index antibody result. Patients with a negative antibody test were somewhat older at index than those with a positive result (mean of 48 versus 44 years). A fraction (18.4%) of individuals who were initially seropositive converted to seronegative over the follow up period. During the follow-up periods, the ratio (CI) of positive NAAT results among individuals who had a positive antibody test at index versus those with a negative antibody test at index was 2.85 (2.73 - 2.97) at 0-30 days, 0.67 (0.6 - 0.74) at 31-60 days, 0.29 (0.24 - 0.35) at 61-90 days), and 0.10 (0.05 - 0.19) at >90 days. Conclusions Patients who display positive antibody tests are initially more likely to have a positive NAAT, consistent with prolonged RNA shedding, but over time become markedly less likely to have a positive NAAT. This result suggests seropositivity using commercially available assays is associated with protection from infection. The duration of protection is unknown and may wane over time; this parameter will need to be addressed in a study with extended duration of follow up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Real-World Evidence — What Is It and What Can It Tell Us?
Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., LaVange, L., Marinac-Dabic, D., Marks, P. W., Robb, M. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmsb1609216 · Cited by 2,063
Self-citationInterpreting Diagnostic Tests for SARS-CoV-2
Sethuraman, N., Jeremiah, S. S., & Ryo, A. (2020) · JAMA · doi:10.1001/jama.2020.8259 · Cited by 1,494
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2025179 · Cited by 1,021
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Genomic evidence for reinfection with SARS-CoV-2: a case study
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N., Gorzalski, A., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30764-7 · Cited by 754
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00902-8 · Cited by 392
What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews
Makady, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2017) · Value in Health · doi:10.1016/j.jval.2017.03.008 · Cited by 374
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30634-4 · Cited by 351
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
Ward, H., Atchison, C., Whitaker, M., Ainslie, K. E. C., Elliott, J., Okell, L., Redd, R., Ashby, D., Donnelly, C. A., Barclay, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21237-w · Cited by 337
False-positive COVID-19 results: hidden problems and costs
Surkova, E., Nikolayevskyy, V., & Drobniewski, F. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30453-7 · Cited by 310
What reinfections mean for COVID-19
Iwasaki, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30783-0 · Cited by 230
Prolonged SARS‐CoV‐2 RNA shedding: Not a rare phenomenon
Li, N., Wang, X., & Lv, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25952 · Cited by 203
Miksad, R. A., & Abernethy, A. P. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.946 · Cited by 193
Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
Stadlbauer, D., Tan, J., Jiang, K., Hernandez, M. M., Fabre, S., Amanat, F., Teo, C., Arunkumar, G. A., McMahon, M., Capuano, C., et al. (2021) · Nature · doi:10.1038/s41586-020-2912-6 · Cited by 174
Ward, H., Atchison, C. J., Whitaker, M. D., et al. (2020) · medRxiv · doi:10.1101/2020.08.12.20173690v2 · Cited by 155
Camm, A. J., & Fox, K. A. A. (2018) · Open Heart · doi:10.1136/openhrt-2018-000788 · Cited by 128
Li, T., Cao, Z., Chen, Y., Cai, M., Zhang, L., Xu, H., Zhang, J., Ma, C., Liu, Y., Gao, L., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26280 · Cited by 102
Recurrence of positive SARS‐CoV‐2 in patients recovered from COVID‐19
Hoang, V. T., Dao, T. L., & Gautret, P. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26056 · Cited by 98
Morone, G., Palomba, A., Iosa, M., Caporaso, T., Angelis, D. D., Venturiero, V., Savo, A., Coiro, P., Carbone, D., Gimigliano, F., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00562 · Cited by 59
COVID-19 Outbreak at an Overnight Summer School Retreat ― Wisconsin, July–August 2020
Pray, I. W., Gibbons-Burgener, S. N., Rosenberg, A. Z., Cole, D., Borenstein, S., Bateman, A., Pevzner, E., & Westergaard, R. P. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6943a4 · Cited by 53
Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity
Agarwal, V., Venkatakrishnan, A., Puranik, A., Kirkup, C., Lopez-Marquez, A., Challener, D. W., Theel, E. S., O’Horo, J. C., Binnicker, M. J., Kremers, W. K., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00375-y · Cited by 51
Considerations for pharmacoepidemiological analyses in the SARS‐CoV ‐2 pandemic
Pottegård, A., Kurz, X., Moore, N. D., Christiansen, C. F., & Klungel, O. H. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5029 · Cited by 43
Lee, P. H., Tay, W. C., Sutjipto, S., Fong, S., Ong, S. W. X., Wei, W. E., Chan, Y., Ling, L. M., Young, B. E., Toh, M. P. H., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1160 · Cited by 34
Cited by
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
Ebinger, J. E., Fert-Bober, J., Printsev, I., Wu, M., Sun, N., Prostko, J. C., Frias, E. C., Stewart, J. L., Van Eyk, J. E., Braun, J. G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01325-6 · Cited by 538
Massarweh, A., Eliakim-Raz, N., Stemmer, A., Levy-Barda, A., Yust-Katz, S., Zer, A., Benouaich-Amiel, A., Ben-Zvi, H., Moskovits, N., Brenner, B., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2155 · Cited by 265
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J. P. A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112911 · Cited by 264
Metadata
- Authors
- Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R., Meyer, W. A., Kaufman, H. W., Anderson, S., Cohen, O., Petkov, V. I., Cronin, K. A., Van Dyke, A. L., Lowy, D. R., Sharpless, N. E., & Penberthy, L. T.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-01
- Volume
- 181
- Issue
- 5
- Pages
- 672
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W3132798068
- Cited by
- 272
- References
- 30
- FWCI
- 19.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.